

Epidemiology of Lupus Nephritis in Egyptian Children

THESIS

Submitted for partial fulfillment of the
Master degree in Pediatrics

By

Tharwa Mostafa El-Kholi

B.Sc. of Medicine, Cairo University

SUPERVISED By

Prof. Dr. Iman Ahmed Ehsan Abd EL-Meguid

Professor of Pediatrics

Faculty of Medicine, Cairo University

Dr. Heba Taher Osman

Lecturer of Pediatrics

Faculty of Medicine, Cairo University

Dr. Samuel Helmy Makar

Lecturer of Pediatrics

Faculty of Medicine, Cairo University

Pediatric Department

Faculty of Medicine, Cairo University

Acknowledgment

First and foremost thanks to “Allah”, the most kind and the most merciful.

I wish to express my sincere gratitude and utmost thanks to **prof. Dr. Eman Ehsan Abd EL-Meguid**, professor of Pediatrics, Faculty of Medicine, Cairo University, for her continuous encouragement, valuable advice and kind supervision.

I am also sincerely thankful to **Dr. Heba Taher Ossman**, Lecturer of pediatrics at the rheumatology and rehabilitation clinic also to **Dr. Samuel Helmy Makar**, Lecturer of pediatrics at the nephrology unit, for their continues supervision and meticulous revision of this work.

I would like also to thank **Dr. Gada Wahby** for her great effort in making the statistical manipulation of this work.

I would like also to thank all the **staff members of the pediatric rheumatology clinic** for their great help in conducting this work.

Deep appreciation to my great parents and brother for their outstanding help and support offered throughout conducting this work.

Abstract

Lupus nephritis is A FREQUENT AND SERIOUS COMPLICATION IN VIRTUALLY MOST CHILDREN WITH SLE ' RANGING FROM MINIMAL INVOLVEMENT TO PROGRESSIVE RENAL FAILURE BECAUSE OF UNDETECTED INCIDENCE OF lupus nephritis and its epidemiology Egyptian children, this study included 100 patients with lupus nephritis following in the rheumatology clinic at Cairo University children hospital and aimed to describe their different clinical , laboratory and pathological presentation , to investigate the clinic pathological correlation and medication received and follow up achieved as well .

KEY WORDS :

Epidemiology ,lupus nephritis , renal biopsy ,
Egyptian children , incidence , statistical value , renal
Presentation , serum creatinine .

Index

	Page
Introduction & aim of work	١
Review of literature	
Systemic lupus erythematosus	٢
Introduction	
Epidemiology	
Pathophysiology	
Clinical features	
Diagnosis	
Assessment of disease activity	
Treatment	
Outcome & mortality rate	
Lupus nephritis	٢٤
Introduction	
Pathogenesis	
Pathology	
Diagnosis	
Clinicopathological correlation	
Treatment	
Complication	
Outcome & mortality rate	
Patients and methods	٥٠
Results	٥٤
Discussion	٦٤
Summary & Conclusion	٧١
Recommendations	٧٣
References	٧٤
Arabic summary	

List of tables

	Page
Table (١): The ١٩٨٢ Revised ACR criteria	١٥
Table (٢): SLE-DAI.....	١٦
Table (٣): (A) The ١٩٩٥ WHO classification of lupus nephritis....	٢٦
(B) The ١٩٩٥ WHO classification of lupus nephritis....	٣١
Table (٤): Correlation between clinical and laboratory finding and pathologic classifications in LN patients.....	٣٥
Table (٥): Auto antibodies present in patients with lupus	٣٨
Table (٦): Complications of lupus and its treatment.....	٤٨
Table (٧): Five-years actuarial survival class IV nephritis over the past ٤٠ years	٤٩
Table (٨): Percent of ACR fulfillment at the onset of the disease	٥٥
Table (٩): The baseline patients' characteristics.....	٥٥
Table (١٠): Initial presentation of SLE in the study group	٥٦
Table (١١): The prevalence of laboratory manifestation	٥٧
Table (١٢): Frequency of pathological changes occurred in the first and second renal biopsies.....	٥٩

Table (١٣): Number and percentage of patients' GFR according to the CKD classes	٦٠
Table (١٤): Serum creatinine follow up to the whole study group	٦٠
Table (١٥): Value s of creatinine follow up and delta creatinine to the whole study group	٦١
Table (١٦): Values of high serum creatinine at the peak of the disease	٦١
Table (١٧): Values of high serum creatinine at their last follow up	٦١
Table (١٨): Percent of immunosuppressive drugs	٦٢
Table (١٩): Follow up creatinine with medications (prednisone & immunosuppressive drugs)	٦٣

List of figures

	Page
Figure (١): Sex distribution of the study group.....	٥٤
Figure (٢): Sex structure at different age groups in our study group	٥٤
Figure (٣): Initial presentation of SLE in the study group	٥٦
Figure (٤): The prevalence of laboratory manifestation.....	٥٧
Figure (٥): Frequency of WHO classes in the <i>first</i> renal biopsy	٥٨
Figure (٦): Frequency of WHO classes in the <i>second</i> renal biopsy	٥٨

List of abbreviations

ACE	: Angiotensin converting enzyme
ACR	: American college of rheumatology
AI	: Activity index
ANA	: Anti nuclear antibody
Anti-sm	: Anti-smith
aPL	: Antiphospholipid
ARBS	: Angiotensin receptor blockers
CCBS	: Calcium channel Blockers
CI	: Chronicity index
CKD	: Chronic kidney disease
CNS	: Central nervous system
CSF	: Cerebro spinal fluid
CT	: Computerized tomography
DNA	: Deoxyribonucleic acid
DPLN	: Diffuse proliferative lupus nephritis
ds-DNA	: Double stranded DNA
EBV	: Epstein Barr virus
ECG	: Electrocardiograph
EM	: Electron microscopy
ESR	: Erythrocyte sedimentation rate
ESRD	: End stage renal disease
FANA	: Fluorescent antinuclear antibody
GFR	: Glomerular filtration rate
HIV	: Human immunodeficiency virus
HLA	: Human leukocyte antigen
HPF	: High power field
IC	: Immune complex
IF	: Immunofluorescence
Ig	: Immunoglobulin
IV	: Intravenous
IVIG	: Intravenous immunoglobulin
LA	: Lupus anticoagulant
LAI	: Lupus activity index

LE	: Lupus erythematosus
LM	: Light Microscopy
LMN	: Lupus membranous nephropathy
LN	: Lupus nephritis
MCTD	: Mixed connective tissue disease
MRI	: Magnetic resonance imaging
MTX	: Methorexate
NIH	: National institute of health
NPLE	: Neuropsychiatric lupus erythematosus
NSAID	: Non steroidal anti-inflammatory drugs
RBC'S	: Red blood corpuscles
RNP	: Ribonucleoprotein
RTA	: Renal tubular acidosis
SD	: Standard deviation
SLAM	: Systemic lupus activity measure
SLE	: Systemic lupus erythmatosus
SLE-DAI	: SLE-disease activity index
SSA	: Sjogren syndrome A
SSB	: Sjogren syndrome B
TES	: Thrombotic events
UV	: Ultraviolet
WBC'S	: White blood corpuscles
WHO	: World health organization

Introduction and aim of work

Introduction:

Renal disease in systemic lupus erythematosus is a major clinical problem, responsible for significant morbidity and mortality (**Herrare, 1999**). The rate of organ involvement is higher in the child compared with the adult's lupus patients with clinical symptoms of renal involvement occurring in 30% -70% of patients (**Niaudet, 2000**).

Clinical presentation varies from asymptomatic urinary abnormalities to acute nephrotic and/or nephritic syndrome (**Lim et al., 1999**). The exact incidence of renal disease in SLE patient is unknown and it is important to recognize that the spectra and severity of renal disease vary considerably from one patient to another which has both prognostic and therapeutic implications (**Schur, 1997**).

The prognosis for patient with SLE has improved dramatically but in patient with lupus nephritis the prognosis continues to be guarded despite treatment and many patients progress to chronic renal failure (**McCurdy et al., 1997**).

Aim of work:

The aim of this work is to trace the incidence of lupus nephritis among Egyptian children regarding their number with different clinical, laboratory and pathological presentation, medication received and follow up achieved as well.

Systemic Lupus Erythematosus

Introduction:

Systemic lupus erythematosus is an episodic multisystem disease characterized by wide spread inflammation of the blood vessels and connective tissue, it is regarded as a prototype of autoimmune disease in humans on a background of a genetic predisposition of the disease (**Cassidy and petty, 1990**).

This disease occurs primarily in young women and ranges in severity from a mild disease with rash and arthritis to a devastating illness with renal failure and profound nervous system disturbance (**Pisetsky et al., 1997**). Within the past three decades, as treatment modalities have improved life expectancy of children diagnosed with SLE, a new concept of irreversible organ damage has provided a better understanding of lupus as a chronic disease (**Pongmartufani et al., 2007**).

Epidemiology of SLE:

- Incidence & prevalence:

According to lupus foundation, approximately 1.0 million people, mostly women of reproductive age have been diagnosed with SLE (**Emre et al., 2007**). The incidence varies with age, race, sex (**Sibgsen, 1990**), the overall age standardized one-year period prevalence rate as estimated by a recent study of a geographically complete cohort from Nottingham is at 24.7 per 100,000 (**Hopkinson et al., 1994**).

Data from pediatric rheumatic disease registries confirm that SLE accounts for less than 1 percent of patients in pediatric rheumatology clinics in the United Kingdom (**Symmon et al., 1994**).

- Age onset:

10-20 % of SLE patients were diagnosed for the first time during childhood (**Emre et al., 2001**). The peak childhood onset between 11 and 15 years of age, rarely does it affect children below the age of 5 (**Pongmaritani, 2000**).

- Sex ratio:

SLE occurs 10 times more commonly in women than in men, the overall prevalence of SLE in women is approximately 100 per 100,000 (**McCarty et al., 1999**). There are approximately 3 million women and 300,000 men affected worldwide. In one study involving Turkish children, the ratio of female to male children affected with SLE was 9,8 : 1 which is much higher than 4,0 : 1 ratio found in other pediatric studies (**Emre et al., 2001**).

- Race and geography:

Rates of SLE were found to be highest in African American females and lowest in white males (**McCarty, 1999**) and studies suggest that African American and Hispanic children have a higher incidence of SLE.

Black children have a greater prevalence for more severe renal and neuropsychiatric disease, more discoid rash and increased prevalence of cardiac disease as a result of complication of **SLE** (**Stichweil, Arce & Pascual, 2004**).

Pathophysiology:

- Genetics:

Epidemiology data on the familial aggregation, sibling ratio and the disease concordance rate in twins all support a genetic component (**Priori et al., 2007**).

The prevalence of SLE is estimated to be 2.6 to 3.0 % in the first degree relatives of SLE and the risk of developing the disease in sibling is 10-40

times higher than that in the general population the concordance rate in monozygotic twins (24 to 56 %) compared to dizygotic twins (2 to 5 %) (Jarvinen et al., 1992). Several case control studies have identified several genes, providing highly convincing evidence for allelic association with SLE (**Gaffrey et al., 2000**). Eight loci that best support SLE susceptibility have been identified this far including 1q23, 1q25-31, 1q41-42 (located on chromosome 1) 2q35-37 (Located on chromosome 2) 4p16-15.2 (Located on chromosome 4), 6p11-21 (Located on chromosome 6), 12p24 (Located on chromosome 12) and 16q12 (Located on chromosome 16) (Koskenmies et al., 2004). All eight of these loci have been confirmed in at least one independent cohort for linkage to SLE. Locus 16q12 is linked to both SLE and other at autoimmune disease suggesting an interaction with other susceptibility loci which manifest multiple autoimmune diseases (**Cantor et al., 2004**).

- Immunological abnormalities:

SLE is an immune complex (IC)-associated systemic autoimmune disease. The production of abnormal antibodies by polyclonal B cell is the hallmark sign of this disease (**Kammer, 2007**). In people with a predisposition for SLE, cellular antigens exposed during apoptosis may incite the immune response (Pongmarutani et al., 2006). The initiation of the immune response is characterized by the presence of activated helper T cell that induce a B cell response, leading to hyperglobulinemia, the secretion of pathogenic autoantibodies (antidouble stranded DNA antibody and anti-smith) and the formation of immune complex.

The T cells are unable to suppress the B cell clones because of T cell deregulation, resulting in excess CD4, T cell activity and deficient CD8, cytotoxic suppressors function (Kammer, 2002). Additionally B and T cell interaction is facilitated by several cytotoxines (interleukin -10) and co-

stimulatory molecules (CD ϵ 0/CD ϵ 0L,B γ /CD γ 0/CTLA- ϵ) which initiate the interactions along with the body's impaired phagocytic clearance of IC perpetuate the immune response that lead to tissue injury (**Mok & Lau** , 2007) .

- Complement deficiency:

While the activation of complement is involved in tissue damage, inherited deficiencies of components of the classic pathway are strongly associated with the development of SLE. Lupus develops in many patients with complete deficiencies in C γ q (90%) & C ϵ (70%), suggesting that these molecules have a protective role against the development of the disease (**Pickering Mc et al.**, 2000). The protective role of C γ q has been confirmed by the observation of severe lupus nephritis in C γ q deficient mice.

- Hormonal factors:

Females are affected at least five to nine times more frequently than males which suggest an estrogen-mediated immune hyperactivity, it has been noted the activity of SLE is increased in the 2 weeks preceding menstruation (**Cassidy & Petty**, 1990), during which the level of estrogen is increased. The use of oral contraceptives with high level of estrogen were reportedly associated with the lupus activity but more recent reports in which the estrogen dose was much lower failed to show a relationship with the disease activity (**Julkunen**, 1991).

- Environmental Factors:

✦ **Ultraviolet B irradiation:**

Ultraviolet B result in photooxidation and degradation of native DNA in the skin, thereby increasing its Immunogenicity (**Casciola, Rosen**, 1991). Exposure of skin to UV lights results in movement of Ro (SS.A), La (SS-B) and U γ RNP antigens to the surface of keratinocytes where they

might be bound by sensitized T cells or antibodies resulting in a flare of lupus dermatitis (**Than, 2001**).

✦ **Infection:**

Infection have been postulated to play a role in the initiation of the disease, the pathogen which have been extensively studied include Epstein Barr virus EBV, Cytomegalovirus and parvovirus B-19 (**Cooper et al.; Hayashi et al., 1994**). Enzyme linked immunosorbent assay test have been used to link EBV as an environmental trigger (**James, Harley and Scofield, 2001**), to large cohort and found that those with SLE were positive as compared to matched control group.

Eleven percent of SLE patient showed evidence of infection with hepatitis C virus compared to 1% of matched control using third generation recombinant immoblot assay and PCR (**Ramos Casal et al., 2000**). Case studies involving cytomegalovirus and parvovirus B-19 and SLE have increased interest in both of these viruses and their relationship to SLE (**Diaz et al., 2002**).

✦ **Drugs and chemicals:**

Several drugs particularly those metabolized by a acetylation in the liver, such as procainamide or hydralazine, can induce a lupus like syndrome (**Fritzele, 1994**). Other drugs as penicillamine, Isoniazid, interferon-alpha methyl dopa, chlorpromazine and diltiazem are all likely causes of lupus like syndrome.

Anticonvulsants (e.g phenytoin, mephenytion, trimethadone, ethosuximide) quinidine, antithyroid drugs and antimicrobial agents (e.g. sulfonamides, rifampicin) may possibly induce lupus (**Grant, 1990**). Clinical manifestations associated with the drug-induced lupus include fever, cutaneous rash, arthralgia and serositis, whereas renal, hematological or neurological symptoms are rare.